Chronic abdominal pain is the most common gastrointestinal issue and contributes to the pathophysiology of functional bowel disorders and inflammatory bowel disease. Current theories suggest that neuronal plasticity and broad alterations along the brain-gut axis contribute to the development of chronic abdominal pain, but the specific mechanisms involved in chronic abdominal pain remain incompletely understood. Accumulating evidence implicates glial cells in the development and maintenance of chronic pain. Astrocytes and microglia in the central nervous system and satellite glia in dorsal root ganglia contribute to chronic pain states through reactive gliosis, the modification of glial networks, and the synthesis and release of neuromodulators. In addition, new data suggest that enteric glia, a unique type of peripheral glia found within the enteric nervous system, have the potential to modify visceral perception through interactions with neurons and immune cells. Understanding these emerging roles of enteric glia is important to fully understand the mechanisms that drive chronic pain and to identify novel therapeutic targets. In this review, we discuss enteric glial cell signaling mechanisms that have the potential to influence chronic abdominal pain. (Cell Mol Gastroenterol Hepatol 2019;7:433-445; https://doi.org/10.1016/j.jcmgh.2018.11.005)

Keywords: Glial Cells; Enteric Glia; ENS; Abdominal Pain; Chronic Pain; Inflammation; Brain-Gut Axis.

Abdominal pain is the most common gastrointestinal (GI) issue and results in more than 15 million office visits per year.¹ Chronic abdominal pain affects at least 10%–15% of the general population and is a characteristic feature of functional bowel disorders, such as irritable bowel syndrome (IBS), the inflammatory bowel diseases (IBDs), and is a growing problem associated with chronic opioid use.²–⁴ Acute abdominal pain is associated with inflammatory flare-ups in IBD, but a large subset of patients
that suffer from IBD eventually develop chronic abdominal pain even after achieving clinical remission. This condition, called comorbid IBS (loosely termed “IBS-IBD”), is present in up to 46%–59% of patients with Crohn’s disease and 36%–38% of patients with ulcerative colitis in remission.\(^6\) Abdominal pain linked to these disorders is common in adults and pediatric patients and is a major contributing factor to their low quality of life and high morbidity. As a result, the US Food and Drug Administration now requires the use of abdominal pain as a patient-reported outcome to assess the efficacy of new therapies for Crohn’s disease.\(^2\)

The mechanisms that drive the development of chronic abdominal pain remain largely unresolved and this presents a major barrier to progress in the development of new therapies. Current therapies for IBD, for example, primarily focus on controlling inflammation with amino salicylates, corticosteroids, immunomodulators, and biologic agents. Although these agents clearly benefit the treatment of active inflammation, they do not address abdominal pain.\(^3\) Opioids are the current frontline therapy for chronic abdominal pain, but chronic opioid use has serious complications and produces a condition called narcotic bowel syndrome that is characterized by abdominal pain.\(^4\) This is a serious and growing issue that requires a more sophisticated understanding of the causal mechanisms to permit the development of more effective therapies.

Current theories suggest that neuronal plasticity involving the sensitization of visceral afferent sensory nerve fibers and broad alterations to the brain-gut axis contribute to the development of chronic abdominal pain.\(^9,10\) Much of this theory is based on evidence demonstrating changes in neuronal sensitivity, firing patterns, and network activity in the periphery, brain, and spinal cord.\(^11,12\) Although little is still known regarding the mechanisms that drive these alterations to neurons and their networks, it is increasingly clear that these properties are regulated by glia.

Here we discuss evidence supporting the concept that changes to glia contribute to mechanisms involved in the development of abdominal pain. We primarily focus on enteric glia in this review because of their potential to interact with nociceptors in the intestine and the potential consequences of these interactions on the generation of abdominal pain. Furthermore, the topic of central glia in pain transmission has been well covered by recent reviews.\(^10,15\) However, readers should note that alterations to central glia play a major role in pain transmission and, in fact, much of the understanding of glia in neuropathic pain conditions comes from research on glia in central circuits. A more sophisticated understanding of how central and peripheral glia regulate neural activity and how changes to these properties contribute to altered transmission or perception of sensory stimuli in the intestine holds great potential to advance the field of abdominal pain research and to identify novel therapeutic targets. In this review we aim to amass the existing evidence implicating enteric glia as major contributors to peripheral sensitization of nerve afferents and highlight their potential roles in the cause of chronic abdominal pain.

**Known Mechanisms That Contribute to Abdominal Pain**

Visceral hypersensitivity is a major mechanism that contributes to abdominal pain in IBS and IBD.\(^16\) This involves alterations along the brain-gut axis, a network of afferent and efferent neural pathways that link cognitive, emotional, and autonomic centers in the brain to neuroendocrine centers, the enteric nervous system, the gut microbiome, and the immune system. The sensitization of visceral afferent nerve fibers is driven by neuroplasticity and leads to a skewed perception of sensory stimuli. Nociceptive information is transduced by the peripheral axon terminals of primary afferent neurons whose cell bodies reside in dorsal root ganglia (DRG). These “nociceptors” are the axon terminals of polymodal C fibers that transduce a variety of potentially noxious stimuli (mechanical, chemical, and thermal) to the brain. The sensitivity of nociceptors is one of the most important factors that gates the transmission of nociceptive information and alterations to nociceptor sensitivity in GI disorders can lead to an increased perception of pain (hyperalgesia) or the painful perception to innocuous stimuli (allodynia).

Immune activation and neuroplasticity are 2 key mechanisms involved in the generation of chronic abdominal pain. Nociceptor sensitivity is profoundly altered by inflammatory mediators.\(^17\) Active inflammation, such as an IBD flare-up or acute gastroenteritis, involves the release of proinflammatory mediators that alter nociceptor sensitivity. Inflammatory mediators including adenosine triphosphate (ATP),\(^18\) histamine,\(^19\) interleukin (IL)-1\(^β\),\(^20\) proteases,\(^21\) and bradykinins\(^22\) cause pain by interacting with receptors on nociceptors. Other inflammatory mediators, such as IL-6\(^23\) and tumor-necrosis factor (TNF)-α,\(^24\) lead to the sensitization of nociceptors through indirect mechanisms. Nociceptors, themselves, also contribute to local inflammation (termed “neuro-inflammation”) through axon reflexes that produce inflammatory mediators including substance P, neurokinin A, ATP, and calcitonin-gene related peptide.

Neuroimmune activation following a psychological stressor or peripheral inflammation results in neuroplastic changes along nerve afferents that contribute to visceral hyperalgesia.\(^25,26\) Neuroimmune modulators drive neuroplasticity through mechanisms that include the down-regulation of glutamate transporters and the subsequent upregulation of synaptic glutamate and the ionotropic glutamate receptor, N-methyl-D-aspartate, signaling.\(^27,28\) Neuroplastic changes in the expression and function of transient receptor potential vanilloid receptor type-1 (TRPV1) channels present on nociceptors innervating the intestinal mucosa are also implicated in visceral hypersensitivity in IBS.\(^29\) Increased levels of TRPV1 are present in patients with idiopathic rectal hypersensitivity\(^30\) and an increased density of TRPV1 immunoreactive nerve fibers is present in the colonic mucosa of patients with IBS, correlating with the degree of abdominal pain experienced.\(^31\)

Alterations to emotional circuits of the brain, primarily those associated with stress and anxiety, contribute to visceral
hypersensitivity in patients with IBS. Various stressors, chronic and acute, regulate visceral pain responses in animal models and are associated with an increase in symptom severity in functional and inflammatory GI disorders. Brain regions associated with visceral pain, emotional arousal, and attention are consistently activated in neuroimaging studies of patients with IBS. Furthermore, alterations to gray matter density in areas associated with corticolimbic inhibition, stress, and arousal circuits indicate altered activity in the brains of patients with IBS. The activation of these regions contributes to acute and chronic stress-induced hyperalgesia in the colon, in part, by stimulating the release of factors, such as corticotropin-releasing factor.

Glial Cells in Abdominal Pain Pathways

A plethora of emerging studies link nerve fiber sensitization with alterations to glial cells. Increased glial activity is characteristic of all forms of pain and glia contribute to the transition from acute to chronic pain through interactions with neurons that alter neurotransmission.

For example, increases in astrocyte and microglial cell markers are present in animal models of acute pain, inflammatory pain, and neuropathic pain. Structural changes and altered signaling in peripheral glial cells, such as satellite glia in DRG, are implicated in abdominal pain pathways. Furthermore, enteric glial cells, a unique class of peripheral glia found within the enteric nervous system, have bidirectional interactions with neurons in the gut that impact both gut reflexes in health and neuroinflammation. Therefore, an emerging theme is that glia present at all sites along ascending and descending pathways that transduce and modify nociceptive information deriving from the intestine have the potential to broadly influence visceral perception.

Most of the understanding of glia in pain transmission stems from studies of glia at the first synapse in ascending pain pathways in the dorsal horn of the spinal cord. Microglia and astrocytes are the major glial cell types implicated in altering pain transmission at this level. Microglial activation in the spinal cord occurs in response to injury or inflammation and is reflected by increased cell

Figure 1. Major populations of glia that contribute to chronic pain. Astrocytes and microglia are present in the central nervous system and primarily affect chronic pain pathways in the brain and in the spinal cord. Satellite glia are peripheral glial cells located in the dorsal root ganglia where they contribute to the sensitization of dorsal root ganglion cells. Enteric glial cells are located within the intestine and form part of the enteric nervous system. Enteric glia are located adjacent to the nerve endings of primary afferent fibers and intercellular interactions between enteric glia and neurons have the potential to influence chronic pain.
number and altered gene expression profiles.\textsuperscript{15,46,54,55} Likewise, spinal astrocytes become activated and undergo reactive gliosis in animal models of neuropathic pain and increased expression of glial fibrillary acidic protein (GFAP), a marker of reactive astrocytes, mirrors the intensity of pain hypersensitivity.\textsuperscript{46,55,56} The inhibition of astrocyte activity results in a significant attenuation of inflammatory hyperalgesia, suggesting that astrocytic activation is at least partly necessary for the development of pain.\textsuperscript{27} Evidence from studies using in vivo optogenetics suggests that the selective activation of spinal astrocytes is sufficient to increase pain hypersensitivity.\textsuperscript{26} There is still much controversy surrounding glial optogenetic data, because several studies suggest that the activation of astrocytes driven by channelrhodopsin is an effect of cell swelling and is not driven by normal calcium signaling pathways.\textsuperscript{58} Alternative methods of glial-specific activation that more closely reflect physiological mechanisms, such as designer receptors exclusively activated by designer drugs, should be implemented to further validate these findings.

Glial activity in the spinal cord contributes to neuroplasticity, in part by stimulating the release of glial-derived substances termed “gliotransmitters.” Active glial cells produce several proinflammatory mediators that contribute to the activation and sensitization of nerve fibers to central sensitization in the dorsal horn.\textsuperscript{10} For example, TNF-\(\alpha\) produced by spinal microglia and astrocytes contributes to hyperalgesia and allodynia in preclinical pain models.\textsuperscript{59,60} TNF-\(\alpha\) released by astrocytes and microglia also contributes to central sensitization and neuroplasticity through mechanisms that involve the downregulation of glutamate transporters and subsequently, glutamate excitotoxicity.\textsuperscript{28} Other key gliotransmitters, such as purines, activate nerve fibers directly\textsuperscript{18} and in animal models of chronic pain, astrocytes increase the release of ATP and the production of proalgesic mediators, such as glutamate, cytokines, and chemokines.\textsuperscript{10}

Glia mechanisms similar to those occurring in the spinal cord may also affect processing in the brain. Although less is known regarding the contributions of glia in the brain to pain conditions, increased astrocyte activity is observed in the nucleus of the solitary tract following colonic inflammation.\textsuperscript{61} Likewise, microglial activation within the thalamus occurs following nociceptive spinal cord injury.\textsuperscript{62} Alterations to glia in the brain are likely associated with the emotional experience of pain and can be correlated with mood disorders, such as depression and anxiety.\textsuperscript{63}

Multiple populations of peripheral glial cells actively contribute to modifying pain transmission through effects on nociceptors. For example, satellite glia play crucial roles in visceral sensitization. Satellite glia are located in peripheral sensory ganglia where they envelop neuronal cell bodies.\textsuperscript{64} A recent review by Hanani\textsuperscript{47} thoroughly covered the topic of satellite glia in the development and maintenance of chronic pain. To briefly summarize, satellite glia undergo cell division and upregulate their production of GFAP following inflammation or injury to peripheral nerves and express and release proinflammatory cytokines including TNF-\(\alpha\) and IL-1\(\beta\). In addition, satellite glia increase gap-junction mediated coupling following nerve injury and inflammation. These changes to satellite glia are linked to GI pain and are also implicated in chronic abdominal pain in IBS.

**Potential Roles of Enteric Glia in Abdominal Pain**

Enteric glial cells are a unique class of peripheral glia that are associated with neurons in the enteric nervous system. Enteric glia play instrumental roles in gut reflexes that regulate motility and secretion, influence the epithelial barrier, and modulate neuroinflammation.\textsuperscript{79,65} Yet how enteric glia might influence visceral hypersensitivity and nociceptor sensitization is still relatively unknown.

Enteric glia, particularly those associated with neurons in the myenteric plexus, share some morphologic and functional properties with astrocytes that might suggest similar roles in pain transmission. For example, enteric glia express molecular markers, such as GFAP\textsuperscript{66} and S100\(\beta\); provide trophic and protective support to enteric neurons\textsuperscript{68,69}; exhibit activity encoded by intracellular calcium signaling in response to neurotransmitters; and release gliotransmitters through membrane channels composed of connexin-43 (Cx-43).\textsuperscript{52} Connexins are a major structural component of gap junctions and hemichannels in glia and connexin-mediated glial mechanisms play a crucial role in development of chronic neuropathic pain.\textsuperscript{70} Bidirectional communication between enteric neurons and glia mediated by the Cx-43-dependent release of enteric gliotransmitters regulates gut reflexes that control motility and secretions\textsuperscript{56,52,53,71} and the Cx-43-dependent release of gliotransmitters, such as ATP, during neuroinflammation drives neurodegeneration through the activation of neuronal P2X7 receptors.\textsuperscript{51,72} Enteric glia are intimately associated with nociceptors in the intestine and the activation of TRPV1\textsuperscript{73} sensory neurons within the myenteric plexus elicits glial activity and gliotransmitter release through similar mechanisms.\textsuperscript{73} Whether gliotransmitters subsequently have direct or indirect effects on nociceptor activity or sensitivity is still unknown, but this remains an active area of research.

Enteric glia are targets of stress, which is a primary component in the development of visceral hypersensitivity. Several forms of stress, such as chronic stress and early life stress, alter glial signaling and contribute to pain sensitivity in IBS.\textsuperscript{32} The contribution of enteric glia to stress-induced hyperalgesia is still undefined. However, early life stress causes structural changes in enteric glial cells that are correlated with inefficient gastric motility.\textsuperscript{74} Furthermore, stress activates sympathetic pathways in the intestine that activate enteric glia via purinergic transmission.\textsuperscript{75}

Enteric glia contribute to intestinal inflammatory and immune responses\textsuperscript{76} and interact with, and express, cytokines and immunoregulatory signals that contribute to altered nociceptive signaling.\textsuperscript{76–78} Altered immune responses are key components in the development of chronic pain and mediators that sensitize nociceptors, such as neurokinin A,\textsuperscript{73} substance P,\textsuperscript{73} proteases,\textsuperscript{76} and TRPV4\textsuperscript{40} agonists, all elicit responses in enteric glia. This raises the possibility that enteric glia contribute to nociceptor
sensitization caused by these mediators. In support, perturbing enteric glial metabolism with fluorocitrate reduces visceromotor responses in mice.81 Together, these multiple lines of evidence suggest that crosstalk between enteric glia and nociceptors contributes to mechanisms that drive visceral hypersensitivity (Figure 2). The precise mechanisms by which enteric glia influence nociceptors are still being discovered. Yet new data discussed in the following sections are offering promising leads that could identify novel molecular targets for new abdominal pain therapies.

Potential Mechanisms for Direct Modulation of Nociceptors by Enteric Glia

Enteric glia play active roles in neurotransmission in the intestine by generating and regulating the availability of neurotransmitters. Many of the transmitter systems regulated by enteric glia are involved in the activation and sensitization of nociceptors. For example, enteric glia are a primary source of ATP, which contributes to cell-to-cell communication in health and disease and acts on P2X receptors expressed by nociceptors.19,51,82,83 Purines and purinergic signaling from glial cells are altered during inflammation and are strongly implicated in the process of visceral hypersensitivity and abdominal pain.84,85 Glial cells, including enteric glia, also possess ectoenzymes, such as NTPDase2, that are responsible for the degradation of ATP and other transmitters.51,86,87 Astrocytic NTPDase2 expression is altered during inflammation and could contribute to the sensitization of sensory neurons by increasing purinergic signaling.87 The similarities between enteric glia and astrocytes suggest that a similar behavior could be observed in enteric glia. Glial ATP release is triggered by the excitation of enteric glial cells, intracellular calcium signaling, and the subsequent opening of Cx-43 hemichannels,51 which is a molecular mechanism highly implicated in the development of nociceptive pain and inflammatory pain.51,70,88 In spinal astrocytes, Cx-43 expression is highly elevated following spinal cord injury and the inhibition of Cx-43 reduces allodynia and hyperalgesia.70,88,89 A direct link between Cx-43 on enteric glial cells and nociceptors sensitization has yet to emerge. However, because of the implications of astroglial Cx-43 in chronic pain and the analogous nature of enteric glia, it is likely that enteric Cx-43 is readily involved in the mechanisms of abdominal pain. In support, we recently showed that bidirectional communication between nociceptors and enteric glia involves glial Cx-43.73

Proinflammatory cytokines including IL-6, IL-1β, and TNF-α play major roles in the development of intestinal
pathology and are known contributors to the development and maintenance of inflammatory and neuropathic pain. These cytokines are increased during IBS and IBD. Astrocytes, microglia, and satellite glia produce proinflammatory cytokines, such as IL-1β, during inflammation and nerve injury. Similarly, enteric glia produce, and respond to cytokines including IL-6 and IL-1β. Experimental studies support a proinflammatory, pronociceptive role for IL-6 and the upregulation of IL-6 correlates with the development of hyperalgesia and allodynia in animal models. Blocking IL-6 production and activity reduces or alleviates nociceptor sensitization. Similarly, IL-1β has proinociceptive effects and treatment with IL-1β in vivo causes increased visceromotor responses to colorectal distention in animal models of inflammatory pain.

Enteric glia also interact with TNF-α signaling pathways and TNF-α is heavily implicated in the development of visceral hypersensitivity. Microglia and satellite glia increase their expression of TNF-α during nerve injury and inflammation and the excitation of DRG neurons in mouse colitis models stimulates TNF-α production. The exogenous application of TNF-α increases DRG neuron activity and visceral pain responses in trinitrobenzene sulfonic acid colitis, which is reversed by the administration of anti-TNF-α. Evidence regarding the production of TNF-α by enteric glia is still controversial. However, TNF-α does alter enteric glial cell behavior and exposure to TNF-α induces increased GFAP expression and calcium signaling in enteric glia. It is possible that these effects are mediated through modifications to Cx-43 hemichannels based on the known effects of TNF-α in spinal cord injury.

Neurotrophic factors, such as nerve growth factor, brain-derived neurotrophic factor (BDNF), and neurotrophin-3, are also associated with neuropathic pain and inflammatory processes. Enteric glia are a significant source, and target of neurotrophins in the intestine and alterations in the expression of neurotrophins and their receptors are associated with changes in enteric glial activity. The upregulation of BDNF expression by DRG neurons contributes to visceral pain and enteric glia in the colon of patients with IBS highly express the BDNF receptor TrkB. In addition, recent data suggest that BDNF-induced colonic hypersensitivity involves reactive enteric glia because visceral pain responses and GFAP expression were reduced in BDNF knockout mice. Similarly, nerve growth factor secretion by cultured enteric glia and mRNA levels of nerve growth factor and its receptor TrkA are increased in the presence of lipopolysaccharide, TNF-α, and IL-1β. Given the multiple biologic roles of neurotrophins in the maintenance of neuronal survival and function, changes in glial neurotrophin expression and/or signaling could contribute to the neuroplasticity involved in visceral hypersensitivity.

The gut microbiome has emerged as an essential component of the brain-gut axis and alterations in the composition of the microbiome are observed in several GI and pain conditions. Altered fecal microbiota in patients with IBS may even predict severity. The microbiota produce a range of neurotransive compounds, such as the neurotransmitters γ-aminobutyric acid, serotonin, norepinephrine, and dopamine and other bacterial products, such as lipopolysaccharide and formyl peptides. This suggests that the gut microbiome could influence pain pathways, but mechanistic links between the gut microbiome, sensory nerves, and alterations in the brain-gut axis are still relatively undefined. New data suggest that some effects of the microbiome could be exerted through effects on enteric glial function and development. The generation of the mucosal enteric glial cell network parallels the maturation of the gut microbiome and the impaired mucosal glial population in germ-free mice can be restored by introducing a normal gut microbiome. The lipopolysaccharide receptor, TLR4, is located on enteric glial cells and is increased in mice following exposure to stress. Visceromotor responses in maternally separated mice can be suppressed with oxtocin, which also causes a downregulation of enteric glial cell activity and TLR4 expression. This is indicative of a TLR4-dependent mechanism of enteric glial cells in modulating visceral pain responses. The gut microbiome also produces several gliomodulators, such as proteases that directly act on enteric glial cells and are implicated in the pathophysiology of visceral hypersensitivity. However, the significance of interactions between the microbiome and glia in the generation of visceral pain is still unknown and requires additional mechanistic studies to unravel.

Potential Mechanisms of Indirect Modulation of Nociceptors by Enteric Glia

Inflammation is a key component in the development of chronic pain and abnormalities in immune responses are considered one of the primary causes leading to the development of IBS. Approximately 10% of all cases of IBS are associated with a previous inflammatory insult, such as a bacterial infection. Immune cells play an important role in the sensitization of sensory nerve fibers during inflammation and contribute to the development of acute and chronic pain. Their active role in pain is primarily caused by the release of proinflammatory mediators that modulate ion channel expression in primary afferent fibers, such as TRPV1 receptors. Histamine, for example, activates nerve fibers and contributes to neurogenic inflammation and pain. Blocking H1 histamine receptors expressed by primary sensory afferent neurons in mice reduces pain responses after cutaneous injection of formalin to the paw.

Recently, the concept that both central and peripheral glial cells function as immunoregulatory cells has emerged. Gial cell–mast cell communication is critical for the development of inflammation. Histamine clearance is an essential process for avoiding excessive histaminergic neuronal activation. Astrocytes play a prominent role in histamine clearance via histamine N-methyltransferase, a histamine metabolizing enzyme. Astrocyte activity is modulated via histamine receptors on...
their cell membrane and microglial activation through histamine results in the subsequent release of inflammatory mediators. Enteric glia exhibit the potential to function through similar pathways because their activity is also increased in the presence of histamine.

Current evidence supports the notion that enteric glia modify immune responses by the secretion of cytokines and other chemical transmitters and/or by acting as antigen-presenting cells. Glial proinflammatory mediators including S100B, ATP, and nitric oxide increase oxidative stress in the local environment and contribute to neuronal cell death and the release of apoptotic signaling that triggers immune responses. Enteric glia are also capable of expressing major histocompatibility complex II molecules and ligands necessary for T-cell signaling. Several types of immune cells are involved in inflammatory pain, particularly in the persistence of hyperalgesia. Immune cell activity can also contribute to neuropathic pain because of damage to peripheral nerves or to the central nervous system. Together these data show that enteric glia can modulate immune cells, which in turn can influence nociception.

Potential Roles of Enteric Glia in Opioid-Induced Hyperalgesia

Current treatments targeting chronic pain are limited and often involve the use of opioids. However, opioid use has serious side effects that include persistent constipation and antinoceptive tolerance that limit clinical efficacy. Opioid-induced hyperalgesia can result from chronic opioid use and produce an IBS-like syndrome termed “narcotic bowel syndrome.” Narcotic bowel syndrome is a subset of opioid bowel dysfunction characterized by recurring abdominal pain that worsens with the continued or escalating use of narcotics.

Glial cells play a role in modulating opioid behavior. Chronic opioid treatment causes glial release of nitric oxide, prostaglandins, excitatory amino acids, and growth factors. It also causes changes in purinergic signaling and increases the release of glial mediators that enhance the release of pain transmission. Opiates modulate central glial activity by directly binding to the glial (μ)-opioid receptor causing the release of proinflammatory cytokines or indirectly through the release of dynorphins. Chronic exposure to opioids leads to robust astrocyte and microglia reactions and induces hyperalgesia. Acute opioid treatment also produces marked satellite glia reaction in DRG. The bulk of these effects result from altered glial purinergic signaling. Chronic opioid treatment leads to the upregulation of P2X4 and P2X7 receptors in spinal microglia and contributes to opioid tolerance. Similar effects are observed in enteric glial cells. Long-term morphine treatment enhances purinergic activity in enteric glia that subsequently leads to barrier dysfunction and constipation through mechanisms that require glial Cx-43 activity. Opioid exposure upregulates proinflammatory cytokine release and contributes to morphine tolerance. Chronic morphine exposure causes the release of TNF-α, IL-1β, and IL-6 from glial cells, all of which are known contributors to chronic pain. Chronic opioid exposure induces glial responses through TLR4 and reinforces the rewarding effects of opioids. Blocking TLR4 signaling attenuates the development of analgesic tolerance and hyperalgesia. Enteric glia express TLR receptors and TLR4-deficient mice fail to develop opioid-induced bowel disfunctions. Although these findings implicate enteric glial cells as playing a major role in morphine-induced bowel dysfunction and opioid tolerance, more in-depth studies are needed to clearly define the role of glia in opioid-induced hyperalgesia.

Conclusions

New therapies are needed to combat the common clinical issue of chronic abdominal pain. However, their development is limited primarily by the incomplete understanding of mechanisms that drive the development and maintenance visceral pain. Recent discoveries suggest that significant new insight into these mechanisms could be gained by focusing on glial cells. Glia are intertwined with mechanisms that produce nociceptive hyperalgesia and allodynia in pathologic conditions. Specifically, glia are responsive to neurotransmitters in pain circuits and produce, secrete, and regulate modulators that activate and sensitize nociceptors. Moreover, glial cells actively contribute to processes involved in neuroplasticity. The precise mechanisms whereby peripheral glia contribute to neuroplasticity in pain pathologies is still a developing area, but current discoveries suggest that these mechanisms are involved in the transition from acute to chronic pain.

The contributions of glial cells to pain hypersensitivity are not centralized, but in fact require the involvement of several glial cell types along the brain-gut axis. Existing knowledge regarding enteric glia suggests that they are involved in visceral hypersensitivity and chronic pain. Enteric glia are primed for immune and stress responses. Increasing evidence supports their role in nociception, because they can influence nerve fiber activity either directly by releasing pronociceptive modulators or indirectly by interacting with the immune system. Their reactivity is also linked with altered ion channel signaling on nociceptor nerve endings. In addition to stress and inflammatory visceral hypersensitivity, enteric glia also show promise in playing a key role in the mechanisms of opioid-induced hyperalgesia and narcotic bowel syndrome.

Enteric glia signaling involving Cx-43 is currently the most well-described glial mechanism that contributes to neuroinflammation and intercellular communication. However, the therapeutic potential of this target is untested. Existing drugs that modulate Cx-43 are poorly selective and interact with connexin hemichannels and gap junctions in multiple tissues and cell types, which could potentially compromise normal gut function. This suggests that targeting mechanisms upstream or downstream of glial Cx-43 may prove more effective. In support, a clinical trial targeting downstream neuronal mechanisms with the P2X7 receptor antagonist AZD9056 showed significant promise in the treatment of visceral pain in patients with Crohn's
References

1. Peery AF, Crockett SD, Barratt AS, Dellon ES, Eluri S, Gangarosa LM, Jensen ET, Lund JL, Pasricha S, Runge T, Schmidt M, Shaheen NJ, Sandler RS. Burden of gastrointestinal, liver, and pancreatic diseases in the United States. Gastroenterology 2015;149:1731–1741.

2. Mansfield KE, Sim J, Jordan JL, Jordan KP. A systematic review and meta-analysis of the prevalence of chronic widespread pain in the general population. Pain 2016; 157:55–64.

3. Longstreth GF, Thompson GW, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006;130:1480–1491.

4. Regueiro M, Greer JB, Szegethy E. Etiology and treatment of pain and psychosocial issues in patients with inflammatory bowel diseases. Gastroenterology 2017; 152:430–439.

5. Keohane J, O’Mahony C, O’Mahony L, O’Mahony S, Quigley EM, Shanahan F. Irritable bowel syndrome–type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? Am J Gastroenterol 2010;105:1789–1794.

6. Minderhoud IM, Oldenburg B, Wissejager JA, Henegouwen GP, Smout A. IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior. Dig Dis Sci 2004;49:469–474.

7. Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2012;107:1474–1482.

8. Colombel J-F, Mahadevan U. Inflammatory bowel disease 2017: innovations and changing paradigms. Gastroenterology 2017;152:309–312.

9. Camilleri M, Lembo A, Katzka DA. Opioids in gastroenterology: treating adverse effects and creating therapeutic benefits. Clin Gastroenterol Hepatol 2017; 15:1338–1349.

10. Ji R-R, Chameissian A, Zhang Y-Q. Pain regulation by non-neuronal cells and inflammation. Science 2016; 354:572–577.

11. Mayer EA, Tillisch K. The brain-gut axis in abdominal pain syndromes. Annu Rev Med 2011;62:381–396.

12. Gold MS, Gebhart GF. Noceceptor sensitization in pain pathogenesis. Nat Med 2010;16:1248–1257.

13. Cervero F, Laird J. Understanding the signaling and transmission of visceral nociceptive events. J Neurobiol 2004;61:45–54.

14. Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell 2009; 139:267–284.

15. Ji R-R, Berta T, Nedergaard M. Glia and pain: is chronic pain a gliopathy? Pain 2013;154(Suppl 1):S10–S28.

16. Serra J, Spiller R. Mechanisms of hypersensitivity in IBS. Gut 2015;64:343–348.

17. Stein C, Machelska H. Modulation of peripheral sensory neurons by the immune system: implications for pain therapy. Pharmacol Rev 2011;63:860–881.

18. Cook S, McCleskey E. Cell damage excites nociceptors through release of cytosolic ATP. Pain 2002;95:41–47.

19. Wouters MM, Balemans D, Wanrooy S, Dooley J, Cibert-Goton V, Alipaz YA, Valdez-Morales EE, Nasser Y, Veldhoven PP, Vanbrabant W, De Merwe S, Mols R, Ghesquière B, Ciriolo C, Kortekaas I, Carmeliet P, Peetemans WE, Vermeire S, Rutgeerts P, Augustijns P, Hellings PW, Belmans A, Vanner S, Bulmer DC, Talavera K, Berge P, Liston A, Boeckxstaens GE. Histamine receptor H1–mediated sensitization of TRPV1 mediates visceral hypersensitivity and symptoms in patients with inflammatory bowel syndrome. Gastroenterology 2016;150:875–887.

20. Binshtok AM, Wang H, Zimmermann K, Amaya F, Vardeh D, Shi L, Brenner GJ, Ji R-R, Bean BP, Woolf CJ, Samad TA. Nociceptors are interleukin-1β sensors. J Neurosci 2008;28:14062–14073.

21. Amadesi S, Cottrell GS, Divino L, Chapman K, Grady EF, Bautista F, Karanja R, Barajas-Lopez C, Vanner S, Vergnolle N, Bunnell NW. Protease-activated receptor 2 sensitizes TRPV1 by protein kinase C-ζ and A-dependent mechanisms in rats and mice. J Physiol 2005; 575:555–571.

22. Bandell M, Story GM, Hwang S, Viswanath V, Eid SR, Petrus MJ, Earley TJ, Patapoutian A. Noxois cold ion channel TRPA1 is activated by pungent compounds and bradykinin. Neuron 2004;41:849–857.

23. Obreja O, Biasio W, Andratsch M, Lips K, Rathee P, Ludwig A, Rose-John S, Kress M. Fast modulation of heat-activated ionic current by proinflammatory interleukin 6 in rat sensory neurons. Brain 2005; 128:1634–1641.

24. Czeschik J, Hagenacker T, Schäfers M, Büsßelberg D. TNF-α differentially modulates ion channels of nociceptive neurons. Neurosci Lett 2008;434:293–298.

25. Azpiroz F, Bouin M, Camilleri M, Mayer E, Poitras P, Serra J, Spiller R. Mechanisms of hypersensitivity in IBS and functional disorders. Neurogastroenterol Motil 2007; 19:62–88.

26. Sengupta JN. Sensory nerves. Handb Exp Pharmacol 2009;194:31–74.

27. Li J, McRoberts JA, Ennes HS, Trevisani M, Nicoletti P, Mittal Y, Mayer EA. Experimental colitis modulates the functional properties of NMDA receptors in dorsal root.
ganglia neurons. Am J Physiol Gastrointest Liver Physiol 2006;291:G219–G228.

28. Sung B, Lim G, Mao J. Altered expression and uptake activity of spinal glutamate transporters after nerve injury contribute to the pathogenesis of neuropathic pain in rats. J Neurosci 2003;23:2899–2910.

29. Jones CR, Xu L, Gebhart G. The mechanosensitivity of mouse colon afferent fibers and their sensitization by inflammatory mediators require transient receptor potential vanilloid 1 and acid-sensing ion channel 3. J Neurosci 2005;25:10981–10989.

30. Chan C, Facer P, Davis J, Smith G, Egerton J, Bountra C, Williams N, Anand P. Sensory fibers expressing capsaicin receptor TRPV1 in patients with rectal hypersensitivity and fecal urgency. Lancet 2003;361:385–391.

31. Akbar A, Yiangou Y, Facer P, Walters J, Anand P, Ghosh S. Increased capsaicin receptor TRPV1-expressing sensory fibers in irritable bowel syndrome and their correlation with abdominal pain. Gut 2008;57:923–929.

32. Larauache M, Mulak A, Taché Y. Stress-related alterations of visceral sensation: animal models for irritable bowel syndrome study. J Neurogastroenterol Motil 2011;17:213–224.

33. Ren T-H, Wu J, Yew D, Ziea E, Lao L, Leung W-K, Berman B, Hu P-J, Sung JJ. Effects of neonatal maternal separation on neurochemical and sensory response to colonic distension in a rat model of irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2006;292:G849–G856.

34. Tramullas M, Finger BC, Moloney RD, Golubeva AV, Moloney G, Dinan TG, Cryan JF. Toll-like receptor 4 regulates chronic stress-induced visceral pain in mice. Biol Psychiatry 2014;76:340–348.

35. Eisenbruch S, Rosenberger C, Bingel U, Forsting M, Schedlowski M, Gizewski ER. Patients with irritable bowel syndrome have altered emotional modulation of neural responses to visceral stimuli. Gastroenterology 2010;139:1310–1319.

36. Drewes A, Frikjaer J, Larsen E, Reddy H, Arendt-Nielsen L, Gregersen H. Pain and mechanical properties of the rectum in patients with active ulcerative colitis. Inflamm Bowel Dis 2006;12:294–303.

37. Bielefeldt K, Davis B, Binion DG. Pain and inflammatory bowel disease. Inflamm Bowel Dis 2008;15:778–788.

38. Tillisch K, Mayer EA, Labus JS. Quantitative meta-analysis identifies brain regions activated during rectal distension in irritable bowel syndrome. Gastroenterology 2011;140:91–100.

39. Seminowicz DA, Labus JS, Bueller JA, Tillisch K, Nailboff BD, Bushnell CM, Mayer EA. Regional gray matter density changes in brains of patients with irritable bowel syndrome. Gastroenterology 2010;139:48–57.

40. Larauache M, Bradesi S, Million M, McLean P, Taché Y, Mayer EA, McRoberts JA. Corticotropin-releasing factor type 1 receptors mediate the visceral hyperalgesia induced by repeated psychological stress in rats. Am J Physiol Gastrointest Liver Physiol 2008;294:G1033–G1040.

41. La J-H. Peripheral corticotropin releasing hormone mediates post-inflammatory visceral hypersensitivity in rats. World J Gastroenterol 2008;14:731–736.

42. Cairns BE, Arendt-Nielsen L, Sacerdote P. Perspectives in pain research 2014: neuroinflammation and glial cell activation: the cause of transition from acute to chronic pain? Scand J Pain 2015;6:3–6.

43. Stuessle SL, Crisp T, McBurney DL, Schechter JB, Lovell JA, Cruce WLR. Neuropathic pain in aged rats: behavioral responses and astrocytic activation. Exp Brain Res 2001;137:219–227.

44. Coyle DE. Partial peripheral nerve injury leads to activation of astroglia and microglia which parallels the development of allodynic behavior. Glia 1998;23:75–83.

45. Sweitzer SM, Colburn RW, Rutkowski M, DeLeo JA. Acute peripheral inflammation induces moderate glial activation and spinal IL-1β expression that correlates with pain behavior in the rat. Brain Res 1999;829:209–221.

46. Tanga F, Raghavendra V, DeLeo J. Quantitative real-time RT-PCR assessment of spinal microglial and astrocytic activation markers in a rat model of neuropathic pain. Neurochem Int 2004;45:397–407.

47. Hanani M. Role of satellite glial cells in gastrointestinal pain. Front Cell Neurosci 2015;9:412.

48. Brown IA, Gulbransen BD. The antioxidant glutathione protects against enteric neuron death in situ, but its depletion is protective during colitis. Am J Physiol Gastrointest Liver Physiol 2018;314:G39–G52.

49. Grubišić V, Gulbransen BD. Enteric glia: the most alimentary of all glia. J Physiol 2017;595:557–570.

50. McClain JL, Fried DE, Gulbransen BD. Agonist-evoked Ca2+ signaling in enteric glia drives neural programs that regulate intestinal motility in mice. Cell Mol Gastroenterol Hepatol 2015;1:631–645.

51. Brown IA, McClain JL, Watson RE, Patel BA, Gulbransen BD. Enteric glia mediate neuron death in colitis through purinergic pathways that require connexin-43 and nitric oxide. Cell Mol Gastroenterol Hepatol 2016;2:77–91.

52. McClain JL, Grubišić V, Fried D, Gomez-Suarez RA, Leinninger GM, Sévigny J, Parpura V, Gulbransen BD. Ca2+ responses in enteric glia are mediated by connexin-43 hemichannels and modulate colonic transit in mice. Gastroenterology 2014;146:497–507.

53. Grubišić V, Gulbransen BD. Enteric glial activity regulates secretomotor function in the mouse colon but does not acutely affect gut permeability. J Physiol 2017;595:3409–3424.

54. Gosselin R-D, Suter MR, Ji R-R, Decosterd I. Glial cells and chronic pain. Neuroscientist 2010;16:519–531.

55. Guo W, Wang H, Watanabe M, Shimizu K, Zou S, LaGraize SC, Wei F, Dubner R, Ren K. Glial-cytokine–neuronal interactions underlying the mechanisms of persistent pain. J Neurosci 2007;27:6006–6018.

56. Romero-Sandoval A, Chai N, Nutille-McMeneny N, DeLeo JA. A comparison of spinal Iba1 and GFAP expression in rodent models of acute and chronic pain. Brain Res 2008;1219:116–126.

57. Nam Y, Kim J-H, Kim J-H, Jha M, Jung J, Lee M-G, Choi I-S, Jang I-S, Lim D, Hwang S-H, Cho H-J, Suk K. Reversible induction of pain hypersensitivity following optogenetic stimulation of spinal astrocytes. Cell Rep 2016;17:3049–3061.
58. Cho W-H, Barcelon E, Lee S. Optogenetic glia manipulation: possibilities and future prospects. Exp Neurobiol 2016;25:197–204.

59. Zhong Y, Zhou L-J, Ren W-J, Xin W-J, Li Y-Y, Zhang T, Liu X-G. The direction of synaptic plasticity mediated by C-fibers in spinal dorsal horn is decided by Src-family kinases in microglia: the role of tumor necrosis factor-α. Brain Behav Immun 2010;24:874–880.

60. Gao Y, Zhang L, Glia JR. Spinal injection of TNF-α-activated astrocytes produces persistent pain symptom mechanical allodynia by releasing monocyte chemoattractant protein-1. Glia 2010;58:1871–1880.

61. Sun Y-N, Luo J-Y, Rao Z-R, Lan L, Duan L, GFAP and Fos immunoreactivity in lumbo-sacral spinal cord and medulla oblongata after chronic colonic inflammation in rats. World J Gastroenterol 2005;11:4827–4832.

62. Zhao P, Waxman SG, Hains BC. Modulation of thalamic nociceptive processing after spinal cord injury through remote activation of thalamic microglia by cysteine–cysteine chemokine ligand 21. J Neurosci 2007;27:8893–8902.

63. Rajkowska G, Miguel-Hidalgo J. Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets 2007;6:219–233.

64. Hanani M. Satellite glial cells in sympathetic and parasympathetic ganglia: In search of function. Brain Res Rev 2010;64:304–327.

65. Gulbransen BD. Do nerves make bowels irritable? Am J Physiol Gastrointest Liver Physiol 2018;315:G126–G127.

66. Jessen K, Mirsky R. Astrocyte-like glia in the peripheral nervous system: an immunohistochemical study of enteric glia. J Neurosci 1983;3:2206–2218.

67. Cocchia D, Michetti F, Ferri G-L, Polak JM, Probert L, Marangos PJ. Evidence for the presence of S-100 protein in the glial component of the human enteric nervous system. Nature 1982;297:409–410.

68. Gulbransen BD, Sharkey KA. Novel functional roles for enteric glia in the gastrointestinal tract. Nat Rev Gastroenterol Hepatol 2012;9:625–632.

69. von Boyen GB, Steinkamp M, Reinshagen M, Schäfer KH, Adler G, Kirsch J. Proinflammatory cytokines increase glial fibrillary acidic protein expression in enteric glia. Gut 2004;53:222–228.

70. Chen MJ, Kress B, Han X, Moll K, Peng W, Ji R, Nedergaard M. Astrocytic CX43 hemichannels and gap junctions play a crucial role in development of chronic neuropathic pain following spinal cord injury. Glia 2012;60:1660–1670.

71. Fried DE, Watson RE, Robson SC, Gulbransen BD. Ammonia modifies enteric neuromuscular transmission through glial γ-aminobutyric acid signaling. Am J Physiol Gastrointest Liver Physiol 2017;313:G570–G580.

72. Gulbransen BD, Bashashati M, Hirota SA, Gui X, Roberts JA, MacDonald JA, Muruve DA, McKay DM, Beck PL, Mawe GM. Activation of neuronal P2X7 receptor–pannexin-1 mediates death of enteric neurons during colitis. Nat Med 2012;18:600–604.

73. Delvalle N, Dharshika C, Morales-Soto W, Fried DE, Gaudette L, Gulbransen BD. Communication between enteric neurons, glia, and nociceptors underlies the effects of tachykinins on neuroinflammation. Cell Mol Gastroenterol Hepatol 2018;6:321–344.

74. Fujikawa Y, Tominaga K, Tanaka F, Tanigawa T, Watanabe T, Fujiwara Y, Arakawa T. Enteric glial cells are associated with stress-induced colonic hyper-contraction in maternally separated rats. Neurogastroenterol Motil 2015;27:1010–1023.

75. Gulbransen BD, Bains JS, Sharkey KA. Enteric glia are targets of the sympathetic innervation of the myenteric plexus in the guinea pig distal colon. J Neurosci 2010;30:6801–6809.

76. Cabarocas J, Savidge TC, Liblau RS. Role of enteric glial cells in inflammatory bowel disease. Glia 2003;41:81–93.

77. Tjwa E, Bradley JM, Keenan CM, Kroese A, Sharkey KA. Interleukin-1β activates specific populations of enteric neurons and enteric glia in the guinea pig ileum and colon. Am J Physiol Gastrointest Liver Physiol 2003;285:G1268–G1276.

78. Rühl A, Franzke S, Collins Stremmel W. Interleukin-6 expression and regulation in rat enteric glial cells. Am J Physiol Gastrointest Liver Physiol 2001;280:G1163–G1171.

79. Garrido R, Segura B, Zhang W, Mulholland M. Presence of functionally active protease-activated receptors 1 and 2 in myenteric glia. J Neurochem 2002;83:556–564.

80. Cenac N, Bautzova T, Faouder P, Veldhuis NA, Poole DP, Rolland C, Bertrand J, Liiedtke W, Dubourdeau M, Bertrand-Michel J, Zacchi L, Stanghellini V, Burnnett NW, Barbara G, Vergnolle N. Quantification and potential functions of endogenous agonists of transient receptor potential channels in patients with irritable bowel syndrome. Gastroenterology 2015;149:433–444.

81. Wang P, Du C, Chen F-X, Li C-Q, Yu Y-B, Han T, Akhtar S, Zuo X-L, Tan X-D, Li Y-Q. BDNF contributes to IBS-like colonic hypersensitivity via activating the enteroglia-nerve unit. Sci Rep 2016;6:20320.

82. Berta T, Park C-K, Xu Z-Z, Xie R-G, Liu T, Lü N, Liu Y-C, Ji R-R. Extracellular caspase-6 drives murine inflammatory pain via microglial TNF-α secretion. J Clin Invest 2014;124:1173–1186.

83. Song D, Li Y, Tang D, Huang L, Yuan Y. Neuron-glia communication mediated by TNF-α and glial activation in dorsal root ganglia in visceral inflammatory hypersensitivity. Am J Physiol Gastrointest Liver Physiol 2014;306:G788–G795.

84. Xu G-Y, Shenoy M, Winston JH, Mittal S, Pasricha PJ. P2X receptor-mediated visceral hyperalgesia in a rat model of chronic visceral hypersensitivity. Gut 2008;57:1230–1237.

85. Deiteren A, van der Linden L, de Wit A, Ceuleers H, Buckinx R, Timmermans J-P, Moreels TG, Pelckmans PA, Man JG, Winter BY. P2X3 receptors mediate visceral hypersensitivity during acute chemically-induced colitis and in the post-inflammatory phase via different mechanisms of sensitization. PloS One 2015;10:e0123810.

86. Lavoie EG, Gulbransen BD, Martín-Satué M, Aliagas E, Sharkey KA, Ségviny J. Ectonucleotidases in the digestive system: focus on NTPDase3 localization. Am J Physiol Gastrointest Liver Physiol 2011;300:G608–G620.
87. Brisevac D, Bajic A, Bjelobaba I, Milosevic M, Stojilkovic M, Beyer C, Clarner T, Kipp M, Nedeljkovic N. Expression of ecto-nucleoside triphosphate diphosphohydrolase1-3 (NTPDase1-3) by cortical astrocytes after exposure to pro-inflammatory factors in vitro. J Mol Neurosci 2013;51:871–879.

88. Tonkin RS, Bowles C, Perera CJ, Keating BA, Makker P, Duffy SS, Lees JG, Tran C, Don AS, Fath T, Liu L, O’Carroll SJ, Nicholson L, Green CR, Gorrie C, Moalem-Taylor G. Attenuation of mechanical pain hypersensitivity by treatment with Peptide5, a connexin-43 mimetic peptide, involves inhibition of NLRP3 inflammasome in nerve-injured mice. Exp Neurol 2018;300:1–12.

89. Choi S-R, Roh D-H, Yoon S-Y, Kwon S-G, Choi H-S, Sawa Y, Oshitani N, Adachi K, Higuchi K, Matsumoto T, Scully P, McKernan DP, Keohane J, Groeger D, White FA, Jung H, Miller RJ. Chemokines and the pathophysiology of neuropathic pain. Proc Natl Acad Sci 2017;114:3852–3861.

90. Bashashati M, Moradi M, Sarosiek I. Interleukin-6 in injured mice. Neuropharmacology 2016;111:34–46.

91. Bashashati M, Moradi M, Sarosiek I. Interleukin-6 expression in a rat mononeuropathy model. J Interferon Cytokine Res 1996;16:695–700.

92. Bashashati M, Moradi M, Sarosiek I. Interleukin-6 in irritable bowel disease. Int J Mol Med 2003;11:175–180.

93. Bashashati M, Moradi M, Sarosiek I. Interleukin-6 in irritable bowel syndrome in females with irritable bowel syndrome and extra-intestinal co-morbidity. Am J Gastroenterol 2010;105:2235–2243.

94. Bashashati M, Moradi M, Sarosiek I. Interleukin-6 in irritable bowel syndrome in females with irritable bowel syndrome and extra-intestinal co-morbidity. Am J Gastroenterol 2010;105:2235–2243.

95. Bashashati M, Moradi M, Sarosiek I. Interleukin-6 in irritable bowel syndrome in females with irritable bowel syndrome and extra-intestinal co-morbidity. Am J Gastroenterol 2010;105:2235–2243.

96. Bashashati M, Moradi M, Sarosiek I. Interleukin-6 in irritable bowel syndrome in females with irritable bowel syndrome and extra-intestinal co-morbidity. Am J Gastroenterol 2010;105:2235–2243.

97. Bashashati M, Moradi M, Sarosiek I. Interleukin-6 in irritable bowel syndrome in females with irritable bowel syndrome and extra-intestinal co-morbidity. Am J Gastroenterol 2010;105:2235–2243.
114. Chichlowski M, O’Mahony SM, Dinan TG, Meerveld B, Cryan JF. Stress and the microbiota–gut–brain axis in visceral pain: relevance to irritable bowel syndrome. Curr Gastroenterol Rep 2011;13:102–117.

115. Moloney RD, Johnson AC, O’Mahony SM, Dinan TG, Meerveld B, Cryan JF. Stress and the microbiota–gut–brain axis in visceral pain: relevance to irritable bowel syndrome. Curr Gastroenterol Rep 2011;13:102–117.

116. Kabouridis PS, Lasrado R, McCallum S, Chng SH, SnippeRNH, Clevers H, Pettersson S, Pachnis V. The gut microbiota keeps enteric glial cells on the move; prospective roles of the gut epithelium and immune system. Gut Microbes 2015;6:398–403.

117. Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, Pettersson S. Host-gut microbiota metabolic interactions. Science 2012;336:1267–1269.

118. Xu S, Qin B, Shi A, Zhao J, Guo X, Dong L. Oxytocin inhibited stress induced visceral hypersensitivity, enteric glial cells activation, and release of proinflammatory cytokines in maternal separated rats. Eur J Pharmacol 2018;818:578–584.

119. Chow AK, Gulbransen BD. Potential roles of enteric glia in bridging neuroimmune communication in the gut. Am J Physiol Gastrointest Liver Physiol 2017;312:G145–G152.

120. Bhave S, Gade A, Kang M, Hauser KF, Dewey WL, Akbarali HI. Connexin-purinergic signaling in enteric glia mediates the prolonged effect of morphine on constipation. FASEB J 2017;31:2660–2666.

121. Ceuleers H, Spaendonk H, Hanning N, Heirbut J, Lambeir A-M, Joossens J, Augustyns K, Man JG, Meester I, Winter BY. Visceral hypersensitivity in inflammatory bowel diseases and irritable bowel syndrome: The role of proteases. World J Gastroenterol 2016;22:10275–10286.

122. Castelli G, Cremon C, Giorgio R, Dethel G, Zecchi L, Bellacosa L, Carini G, Stanghellini V, Corinaldesi R. Mechanisms underlying visceral hypersensitivity in irritable bowel syndrome. Curr Gastroenterol Rep 2011;13:308–315.

123. El-Salhy M. Irritable bowel syndrome: diagnosis and pathogenesis. World J Gastroenterol 2012;18:5151–5163.

124. Franchi S, Sacerdoti P, Panerai A. The prokineticin system: an interface between neural inflammation and pain. Neurrol Sci 2017;38:27–30.
143. Dunn K, Saunders KW, Rutter CM, Banta-Green CJ, Merrill JO, Sullivan MD, Weisner CM, Silverberg MJ, Campbell CI, Psaty BM, Korff M. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med 2010;152:85–92.

144. Chu LF, Angst MS, Clark D. Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. Clin J Pain 2008;24:479–496.

145. Grunkemeier DM, Cassara JE, Dalton CB, Drossman DA. The narcotic bowel syndrome: clinical features, pathophysiology, and management. Clin Gastroenterol Hepatol 2007;5:1126–1139.

146. Watkins LR, Hutchinson MR, Johnston IN, Maier SF. Glia: novel counter-regulators of opioid analgesia. Trends Neurosci 2005;28:661–669.

147. Rattan AK, Tejwani GA. Effect of chronic treatment with morphine, midazolam and both together on dynorphin(1–13) levels in the rat. Brain Res 1997;754:239–244.

148. Ji RR. Targeting microglial purinergic signaling to improve morphine analgesia. Pain 2010;150:377–378.

149. Berta T, Liu T, Liu YC, Xu ZZ, Ji RR. Acute morphine activates satellite glial cells and up-regulates IL-1β in dorsal root ganglia in mice via matrix metalloprotease-9. Mol Pain 2012;8:18.

150. Horvath R, DeLeo JA. Morphine enhances microglial migration through modulation of P2X4 receptor signaling. J Neurosci 2009;29:998–1005.

151. Zhou Z, Peng X, Hao S, Fink DJ, Mata M. HSV-mediated transfer of interleukin-10 reduces inflammatory pain through modulation of membrane tumor necrosis factor α in spinal cord microglia. Gene Ther 2008;15:183–190.

152. Hutchinson MR, Coats BD, Lewis SS, Zhang Y, Sprunger DB, Rezvani N, Baker EM, Jekich BM, Wieseler JL, Somogyi AA, Martin D, Poole S, Judd CM, Maier SF, Watkins LR. Proinflammatory cytokines oppose opioid-induced acute and chronic analgesia. Brain Behav Immun 2008;22:1178–1189.

153. Wei F, Guo W, Zou S, Ren K, Dubner R. Supraspinal glial–neuronal interactions contribute to descending pain facilitation. J Neurosci 2008;28:10482–10495.

154. Hutchinson MR, Zhang Y, Shridhar M, Evans JH, Buchanan MM, Zhao TX, Slivka PF, Coats BD, Rezvani N, Wieseler J, Hughes TS, Landgraf KE, Chan S, Fong S, Phipps S, Falke JJ, Leinwand LA, Maier SF, Yin H, Rice KC, Watkins LR. Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun 2010;24:83–95.

155. Nicotra L, Loram LC, Watkins LR, Hutchinson MR. Toll-like receptors in chronic pain. Exp Neurol 2012;234:316–329.

156. Beckett EA, Staikopoulos V, Hutchinson MR. Differential effect of morphine on gastrointestinal transit, colonic contractions and nerve-evoked relaxations in Toll-Like Receptor deficient mice. Sci Rep 2018;8:5923.

157. Eser A, Colombel JF, Rutgeerts P, Vogelsang H, Braddock M, Persson T, Reinisch W. Safety and efficacy of an oral inhibitor of the purinergic receptor P2X7 in adult patients with moderately to severely active Crohn’s disease: a randomized placebo-controlled, double-blind, phase IIa study. Inflamm Bowel Dis 2015;21:2247–2253.

158. Esposito G, Capoccia E, Turco F, Palumbo I, Lu J, Stardo A, Como R, Sarneil G, Stardo L. Palmitoylethanolamide improves colon inflammation through an enteric glia/toll like receptor 4-dependent PPAR-α activation. Gut 2014;63:1300–1312.

159. Qiao L-Y. Neurotrophin signaling and visceral hypersensitivity. Front Biol 2014;9:216–224.